CV SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0376 USD | -5.16% |
|
-5.28% | +6.50% |
| 03-28 | Transcript : CV Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
| 03-28 | CV Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 16.2M 1.3B | Sales 2023 | 16M 1.28B | Capitalization | 5.47M 438M |
|---|---|---|---|---|---|
| Net income 2022 | -9M -720M | Net income 2023 | 3M 240M | EV / Sales 2022 | 0.36 x |
| Net Debt 2022 | 917K 73.41M | Net cash position 2023 | 875K 70.05M | EV / Sales 2023 | 0.29 x |
| P/E ratio 2022 |
-0.44
x | P/E ratio 2023 |
1.77
x | Employees | 43 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.98% |
More Fundamentals
* Assessed data
More news
Latest transcript on CV Sciences, Inc.
More press releases
| 1 day | -5.16% | ||
| 1 week | -5.28% | ||
| Current month | -8.05% | ||
| 1 month | -3.33% | ||
| 3 months | +1.07% | ||
| 6 months | -0.79% | ||
| Current year | +6.50% |
1 week
0.03
0.04
1 month
0.030.05
Current year
0.030.05
1 year
0.030.06
3 years
0.030.48
5 years
0.035.55
10 years
0.0321.25
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 15/06/14 | |
Joerg Grasser
DFI | Director of Finance/CFO | 49 | 25/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 15/06/14 | |
Jamie Corroon
BRD | Director/Board Member | 54 | 20/07/22 |
William McCorkle
BRD | Director/Board Member | 56 | 20/10/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.0376 | -5.16% | 79,205 |
| 25/04/24 | 0.0397 | 0.00% | 46,553 |
| 24/04/24 | 0.0397 | +4.61% | 92,028 |
| 23/04/24 | 0.038 | 0.00% | 80,457 |
| 22/04/24 | 0.038 | -4.65% | 130,784 |
Delayed Quote OTC Markets, April 26, 2024 at 08:59 pm
More quotes
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). It also operates a drug development program focused on developing and commercializing cannabidiol (CBD)-based therapeutics. It develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under brands, such as +PlusCBD and Cultured Foods in the healthcare market sector, including nutraceutical, beauty care, specialty foods, and pet products. Its +PlusCBD branded products are sold at select retail locations throughout the United States. The Company's Cultured Foods brand provides a variety of 100% plant-based food products and caters to individuals seeking vegan, gluten-free, or flexitarian options for a culinary experience.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +6.50% | 6.15M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CVSI Stock
